Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Glycosylation as a marker for inflammatory arthritis

Glycosylation as a marker for inflammatory arthritis Changes in serum protein glycosylation play an important role in inflammatory arthritis. Altered galactosylation of immunoglobulin G (IgG) in rheumatoid arthritis attracts special attention due to the devastating nature of the disease. Studying glycosylation changes of serum proteins has been recognized as a potential strategy to provide added value regarding diagnostics, aetiopathology and therapy of inflammatory arthritic diseases. Key questions, which are approached in these fields of research, are whether or not glycosylation can be used as a complementary pre-clinical and clinical marker for disease differentiation, diagnosis, the prediction of disease course and severity as well as for the evaluation of disease therapies. These studies mainly focus on TNF antagonists, which present a new and promising way of treating inflammatory arthritis. The recent availability of new high-throughput glycoanalytical tools enables a more profound and efficient investigation in large patient cohorts and helps to gain new insights in the complex mechanism of the underlying disease pathways. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Biomarkers IOS Press

Glycosylation as a marker for inflammatory arthritis

Loading next page...
 
/lp/ios-press/glycosylation-as-a-marker-for-inflammatory-arthritis-nxH0NRkaPs

References (117)

Publisher
IOS Press
Copyright
Copyright © 2014 by IOS Press, Inc
ISSN
1574-0153
eISSN
1875-8592
DOI
10.3233/CBM-130373
pmid
24643039
Publisher site
See Article on Publisher Site

Abstract

Changes in serum protein glycosylation play an important role in inflammatory arthritis. Altered galactosylation of immunoglobulin G (IgG) in rheumatoid arthritis attracts special attention due to the devastating nature of the disease. Studying glycosylation changes of serum proteins has been recognized as a potential strategy to provide added value regarding diagnostics, aetiopathology and therapy of inflammatory arthritic diseases. Key questions, which are approached in these fields of research, are whether or not glycosylation can be used as a complementary pre-clinical and clinical marker for disease differentiation, diagnosis, the prediction of disease course and severity as well as for the evaluation of disease therapies. These studies mainly focus on TNF antagonists, which present a new and promising way of treating inflammatory arthritis. The recent availability of new high-throughput glycoanalytical tools enables a more profound and efficient investigation in large patient cohorts and helps to gain new insights in the complex mechanism of the underlying disease pathways.

Journal

Cancer BiomarkersIOS Press

Published: Jan 1, 2014

There are no references for this article.